GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS (Details Narrative) - USD ($) |
1 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jul. 11, 2024 |
Mar. 08, 2024 |
Aug. 23, 2024 |
Apr. 24, 2024 |
Mar. 25, 2024 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2023 |
|
| Working capital deficit | $ (7,871,228) | |||||||
| Accrued interest | $ 79,492 | |||||||
| Common stock price per share | $ 0.001 | $ 0.001 | ||||||
| Cash | $ 90 | |||||||
| Net cash used in operating activities | (849,084) | $ (1,319,446) | ||||||
| Proceeds from notes payable | 200,000 | 200,000 | ||||||
| Gross Proceeds | $ 594,025 | $ 343,273 | ||||||
| Mr Lucido [Member] | ||||||||
| Promissory note outstanding | $ 446,426 | |||||||
| Professional fees | 90,000 | |||||||
| Accrued interest | $ 7,858 | |||||||
| Common stock shares issued | 460,477 | |||||||
| Common stock price per share | $ 1.18 | |||||||
| Lourdes Felix [Member] | ||||||||
| Professional fees | $ 265,000 | |||||||
| Common stock shares issued | 224,196 | |||||||
| Common stock price per share | $ 1.18 | |||||||
| Investors [Member] | ||||||||
| Common stock shares issued | 15,000 | 15,000 | ||||||
| Gross Proceeds | $ 15,000 | $ 13,350 | ||||||
| Exercise price | $ 1.00 | $ 0.89 | ||||||
| Unsecured Promissory Note Related Third Party [Member] | ||||||||
| Debt instrument term | 9 months | |||||||
| Conversion price | $ 0.75 | 0.75 | $ 0.75 | |||||
| Convertible conversion price decrease | 1.50 | 1.50 | 1.50 | |||||
| Convertible conversion price increase | 2.00 | 2.00 | 2.00 | |||||
| Proceeds from notes payable | $ 200,000 | |||||||
| Interest rate | 8.00% | |||||||
| Exercise price | $ 1.00 | $ 1.00 | $ 1.00 | |||||
| Restricted stock shares issued | 50,000 | 50,000 | 50,000 | |||||
| Restricted stock value | $ 26,000 | $ 26,000 | $ 15,000 | |||||
| Restricted stock price per share | $ 0.52 | $ 0.52 | $ 0.30 | |||||
| Debt instrument lum sum payment | $ 275,000 | $ 275,000 | ||||||
| Debt instrument maturity start date | Aug. 10, 2024 | Sep. 08, 2024 | ||||||
| Debt instrument maturity end date | Sep. 30, 2024 | Oct. 31, 2024 | ||||||
| February 22, 2024 [Member] | ||||||||
| Description of funding | The grant provides for (i) $4,131,123 in funding during the first year, (ii) $3,638,268 during the second-year, and (iii) $3,260,586 during the third-year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds | |||||||
| Award granted by third party | $ 11,029,977 | |||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Increase for accrued, but unpaid interest on the debt instrument for the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from a borrowing supported by a written promise to pay an obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. No definition available.
|
| X | ||||||||||
- Definition Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. No definition available.
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. No definition available.
|
| X | ||||||||||
- Definition Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|